Regenerative Medicine as a Long-Term Alternative to Knee Surgery
An 85-year-old patient with advanced knee osteoarthritis—unresponsive to cortisone and hyaluronic acid injections and previously recommended for total knee replacement—received a multimodal, conservative care protocol that included pulsed electromagnetic field (PEMF) therapy, red light therapy, myofascial release, and a Wharton’s Jelly (WJ) connective tissue allograft application.
Throughout follow-up, the patient reported improvements in discomfort and mobility. Imaging taken six months post-application showed increased joint space compared to baseline. At five years, the patient remained functional with no reported recurrence of the initial symptoms.
A Growing Movement Beyond the Scalpel
Regenerative-first options do not replace surgical care—they expand the continuum of conservative and minimally invasive approaches available to clinicians. These stepwise pathways support informed decision-making and help identify the most appropriate intervention for each patient.
Incorporating regenerative strategies early in care may offer an opportunity to personalize treatment plans, delay the need for invasive procedures, and support long-term functional goals.
A Tissue-Specific Approach to Tissue Degeneration
Wharton’s Jelly does not treat or cure disease—it supplements areas of missing or compromised connective tissue with a biologically familiar matrix. When integrated into compliant, outcomes-focused protocols, WJ allografts can support the structural environment of connective tissues without the cost, risk, or recovery associated with surgery.
Contribute to the Future of Regenerative Care
If your practice uses Wharton’s Jelly allografts, you can join Regenative Labs’ national research registry to share outcomes and help advance scientific understanding in this developing field.